Fusion Antibodies (LSE:FAB) Total Liabilities: £1.09 Mil (As of Sep. 2025)

What is Fusion Antibodies Total Liabilities?

Fusion Antibodies LSE:FAB 33 Total Liabilities is £1.09 Mil as of Sep. 2025. GuruFocus rates LSE:FAB with a GF Score™ of 33/100 and a GF Value™ of £0.04 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Fusion Antibodies's Total Liabilities for the quarter that ended in Sep. 2025 was £1.09 Mil.

Fusion Antibodies's quarterly Total Liabilities increased from Sep. 2024 (£0.47 Mil) to Mar. 2025 (£0.65 Mil) and increased from Mar. 2025 (£0.65 Mil) to Sep. 2025 (£1.09 Mil).

Fusion Antibodies's annual Total Liabilities declined from Mar. 2023 (£0.94 Mil) to Mar. 2024 (£0.63 Mil) but then increased from Mar. 2024 (£0.63 Mil) to Mar. 2025 (£0.65 Mil).

Fusion Antibodies Total Liabilities Related Terms

Fusion Antibodies Total Liabilities Historical Data

* Premium members only.

The historical data trend for Fusion Antibodies's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fusion Antibodies Total Liabilities Chart

Fusion Antibodies Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Total Liabilities

Get a 7-Day Free Trial

1.08

1.23

0.94

0.63

0.65

Fusion Antibodies Semi-Annual Data
	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24	Mar25	Sep25
Total Liabilities	Get a 7-Day Free Trial															0.60	0.63	0.47	0.65	1.09

33GF Score

Fusion Antibodies PLC LSE:FAB

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Fusion Antibodies Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Fusion Antibodies's Total Liabilities for the fiscal year that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.623	+	(0	+	0.031
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	0.65

Total Liabilities	=	Total Assets (A: Mar. 2025 )	-	Total Equity (A: Mar. 2025 )
	=	1.323	-	0.669
	=	0.65

Fusion Antibodies's Total Liabilities for the quarter that ended in Sep. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	0.772	+	(0.283	+	0.031
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	1.09

Total Liabilities	=	Total Assets (Q: Sep. 2025 )	-	Total Equity (Q: Sep. 2025 )
	=	1.812	-	0.726
	=	1.09

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of £1.09 Mil mean?

Fusion Antibodies (LSE:FAB) has a Total Liabilities of £1.09 Mil as of Sep. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Fusion Antibodies and its competitors.

Is Fusion Antibodies' Total Liabilities too high?

Fusion Antibodies' current Total Liabilities is £1.09 Mil. Overall, Fusion Antibodies has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Fusion Antibodies' Total Liabilities compare to VRTX and REGN?

Fusion Antibodies' Total Liabilities of £1.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Biotechnology company?

A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Fusion Antibodies and its competitors. Fusion Antibodies's current Total Liabilities is £1.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Fusion Antibodies stock overvalued right now?

Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.12 — trading 200% above its estimated fair value. The current Total Liabilities is £1.09 Mil. Fusion Antibodies' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current Total Liabilities is £1.09 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fusion Antibodies (LSE:FAB) Overvalued in 2026?

Based on GuruFocus' analysis, Fusion Antibodies stock appears to be overvalued. The current stock price of £0.12 is trading 200% above its estimated GF Value™ of £0.04. GuruFocus considers Fusion Antibodies to be Significantly Overvalued.

Key valuation signals for LSE:FAB:

Total Liabilities: £1.09 Mil
GF Value™: £0.04 vs. price of £0.12 (200% above fair value)
GF Score™: 33/100 with 4 warning signs

No single metric tells the full story. See the LSE:FAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fusion Antibodies Business Description

Industry Healthcare Biotechnology

Comparable Companies LSE:GENF AQSE:PBX LSE:IXI LSE:CIZ LSE:APTA LSE:CRTX LSE:OPTI LSE:IMM LSE:THAT LSE:NFX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 1 Springbank Road, Springbank Industrial Estate, Dunmurry, Northern Ireland, Belfast, GBR, BT17 0QL

Website https://www.fusionantibodies.com

Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.

33GF Score

Get the complete analysis for LSE:FAB

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.12

Price

£0.04

GF Value

View LSE:FAB Analysis

See Total Liabilities data for all stocks →